Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical Carcinoma (AGO-Zervix-1)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01405235 |
|
Recruitment Status : Unknown
Verified September 2006 by Institut fuer Frauengesundheit.
Recruitment status was: Active, not recruiting
First Posted : July 29, 2011
Last Update Posted : April 12, 2012
|
Sponsor:
Institut fuer Frauengesundheit
Collaborators:
GlaxoSmithKline
Schantl Pharma Service, Germany
Information provided by:
Institut fuer Frauengesundheit
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Unknown |
|---|---|
| Estimated Primary Completion Date : | June 2012 |
| Estimated Study Completion Date : | January 2015 |